Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Phase 2 Completed 85 enrolled Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) Amgen · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the objective response rate (ORR) when panitumumab is administered in combination with irinotecan as 2nd-line therapy in subjects with previously treated metastatic colorectal cancer (mCRC).

Timeline

Start: 2007-05
Primary completion: 2010-03
Completion: 2010-03

Publications

Results Carrato A, Gomez A, Escudero P, Chaves M, Rivera F, Marcuello E, Gonzalez E, Gravalos C, Constenla M, Manzano JL, Losa F, Maurel J, Duenas R, Massuti B, Gallego J, Aparicio J, Anton A, Aranda E. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	300 mg/m2	—
Subject	Irinotecan	Small molecule	350 mg/m2	—
Subject	Panitumumab	Monoclonal antibody	9 mg/kg	Intravenous

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Summary

Timeline

Publications

Drugs

Indications